Dermapharm Holding SE (ETR: DMP)

Germany flag Germany · Delayed Price · Currency is EUR
38.05
+0.05 (0.13%)
Dec 20, 2024, 4:32 PM CET
-8.27%
Market Cap 2.05B
Revenue (ttm) 1.17B
Net Income (ttm) 90.59M
Shares Out 53.84M
EPS (ttm) 1.68
PE Ratio 22.63
Forward PE 16.82
Dividend 0.88 (2.32%)
Ex-Dividend Date Jun 28, 2024
Volume 77,348
Open 37.75
Previous Close 38.00
Day's Range 36.95 - 38.30
52-Week Range 30.15 - 43.22
Beta 1.11
Analysts n/a
Price Target n/a
Earnings Date Mar 28, 2025

About Dermapharm Holding SE

Dermapharm Holding SE, together with its subsidiaries, manufactures and sells off-patent branded pharmaceutical products in Germany. The company operates through three segments: Branded Pharmaceuticals and Other Healthcare Products, Parallel Import Business, and Herbal Extracts. It offers branded generics, OTC products, non-prescription healthcare products, and herbal extracts and parallel-imported originator pharmaceuticals. The company also provides vitamins, minerals, food supplements, as well as products for dermatology, allergology, pain a... [Read more]

Sector Healthcare
Founded 1991
Employees 3,497
Stock Exchange Deutsche Börse Xetra
Ticker Symbol DMP
Full Company Profile

Financial Performance

In 2023, Dermapharm Holding SE's revenue was 1.15 billion, an increase of 10.59% compared to the previous year's 1.04 billion. Earnings were 62.37 million, a decrease of -53.54%.

Financial Statements

News

EQS-DD: Dermapharm Holding SE: Dr. Hans-Georg Feldmeier, buy

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 11.11.2024 / 16:30 CET/CEST The issuer is solely responsi...

5 weeks ago - Wallstreet:Online

EQS-DD: Dermapharm Holding SE: Christof Dreibholz, buy

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 05.11.2024 / 15:12 CET/CEST The issuer is solely responsi...

6 weeks ago - Wallstreet:Online

Dermapharm Holding SE: High-Margin Pharma Boosts Global Organic Growth

Dermapharm Holding SE showcases robust organic growth in its branded pharmaceuticals segment, offsetting a revenue dip from the cessation of pandemic-related vaccine production. Unadjusted EBITDA surg...

4 months ago - Wallstreet:Online

EQS-News: Dermapharm Holding SE: High-margin existing business in branded pharmaceuticals segment drives organic growth at German and international companies

EQS-News: Dermapharm Holding SE / Key word(s): Half Year Results/Half Year Report Dermapharm Holding SE: High-margin existing business in branded pharmaceuticals segment drives organic growth at Germa...

4 months ago - Wallstreet:Online

Dermapharm Holding: Thriving on High-Margin Organic Growth in Pharma Business

Despite a slight dip in overall revenue and earnings, strong performance in branded pharmaceuticals has helped Dermapharm navigate the post-pandemic landscape. The company remains optimistic about its...

4 months ago - Wallstreet:Online

EQS-News: Sustained organic growth in high-margin existing branded pharmaceutical business

EQS-News: Dermapharm Holding SE / Key word(s): Half Year Results/Preliminary Results Sustained organic growth in high-margin existing branded pharmaceutical business 14.08.2024 / 07:30 CET/CEST The is...

4 months ago - Wallstreet:Online